Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has chosen renowned contract research organization Hammersmith Medicines Research located in the UK to conduct their Phase 1 stroke program study using DMT.
Moreau talks about the study and also the type of licensing this facility has to be able to do this type of testing.